• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Cal-Maine Foods Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket

    12/29/22 6:36:21 AM ET
    $AMAM
    $ARBK
    $BXRX
    $CALM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $AMAM alert in real time by email

    Gainers

    • Quotient Limited (NASDAQ:QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market.
    • Esports Entertainment Group, Inc. (NASDAQ:GMBL) rose 62.2% to $0.1281 in pre-market trading after declining over 10% on Wednesday. Esports Entertainment Group recently named Alex Igelman as Chief Executive Officer.
    • Baudax Bio, Inc. (NASDAQ:BXRX) shares rose 37.4% to $3.16 in pre-market trading after gaining over 5% on Wednesday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery.
    • AEye, Inc. (NASDAQ:LIDR) rose 28% to $0.64 in pre-market trading. AEye recently promoted T.R. Ramachandran to Chief Operating Officer.
    • Elys Game Technology, Corp. (NASDAQ:ELYS) rose 22.5% to $0.3184 in pre-market trading after dropping around 30% on Wednesday. Elys Game Technology and Cloakbook were recently granted a license to commence sportsbook operations in Washington, D.C.
    • Helbiz, Inc. (NASDAQ:HLBZ) rose 19.6% to $0.1366 in pre-market trading after dropping around 9% on Wednesday.
    • Kala Pharmaceuticals, Inc. (NASDAQ:KALA) rose 16.5% to $14.54 in pre-market trading. Kala Pharmaceuticals shares jumped 218% on Wednesday after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.
    • VistaGen Therapeutics, Inc.. (NASDAQ:VTGN) rose 15.3% to $0.1049 in pre-market trading. Vistagen Therapeutics recently agreed to acquire Pherin Pharmaceuticals Inc in an all-stock transaction of approximately 12.4 million shares.
    • Nuwellis, Inc. (NASDAQ:NUWE) rose 13.4% to $10.40 in pre-market trading. Nuwellis recently announced compliance with Nasdaq listing requirements.
    • Hyzon Motors Inc. (NASDAQ:HYZN) shares rose 12.9% to $1.58 in pre-market trading after the company announced it entered into an equity capital contribution agreement last week with Chevron New Energies, a division of Chevron’s U.S. business, and Raven SR.
    • Smart for Life, Inc. (NASDAQ:SMFL) rose 11.8% to $0.26 in pre-market trading. Smart For Life recently announced the launch of Greens First Protein Bars.
    • TG Therapeutics, Inc. (NASDAQ:TGTX) rose 9.1% to $9.23 in pre-market trading. TG Therapeutics shares gained 8% on Wednesday following FDA approval of ublituximab.
    • HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) rose 8.8% to $3.84 in pre-market trading after dropping 18% on Wednesday. HTG Molecular Diagnostics recently announced the closing of a $10 million offering.
    • Mullen Automotive, Inc. (NASDAQ:MULN) rose 8.4% to $0.23 in pre-market trading. Mullen Automotive recently announced its I-GO Commercial Urban Delivery EV has arrived Europe.


    Losers

    • Argo Blockchain plc (NASDAQ:ARBK) shares fell 14.8% to $0.6251 in pre-market trading. Argo Blockchain shares gained 36% on Wednesday after the company entered into definitive agreements with Galaxy Digital Holdings, under which an Argo subsidiary will sell its Helios facility in Dickens County, Texas for $65 million.
    • Minerva Surgical, Inc. (NASDAQ:UTRS) fell 14.4% to $0.2310 in pre-market trading. Minerva Surgical shares climbed 66% on Wednesday after the company announced a $30 million private placement of common stock led by Accelmed Partners.
    • TransCode Therapeutics, Inc. (NASDAQ:RNAZ) fell 10.5% to $0.5460 in pre-market trading after jumping around 52% on Wednesday.
    • Gaotu Techedu Inc. (NASDAQ:GOTU) fell 10.3% to $2.54 in pre-market trading after dropping 14% on Wednesday.
    • Unicycive Therapeutics, Inc. (NASDAQ:UNCY) fell 10% to $0.45 in pre-market trading after dropping 25% on Wednesday. The company’s pivotal bioequivalence (BE) study comparing Renazorb to Fosrenol met the primary endpoint.
    • Ambrx Biopharma Inc. (NYSE:AMAM) shares fell 9% to $1.41 in pre-market trading after declining around 8% on Wednesday.
    • IsoPlexis Corporation (NASDAQ:ISO) fell 8.3% to $1.43 in pre-market trading. Berkeley Lights recently announced plans to acquire the company for $57.8 million.
    • PureCycle Technologies, Inc. (NASDAQ:PCT) fell 6.4% to $6.00 in pre-market trading.
    • TAL Education Group (NYSE:TAL) fell 5.1% to $7.13 in pre-market trading after dropping around 15% on Wednesday.
    • Cal-Maine Foods, Inc. (NASDAQ:CALM) fell 3.5% to $60.00 in pre-market trading. Cal-Maine Foods reported downbeat earnings for its second quarter, while sales topped expectations.
    Get the next $AMAM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMAM
    $ARBK
    $BXRX
    $CALM

    CompanyDatePrice TargetRatingAnalyst
    TAL Education Group
    $TAL
    1/30/2026$18.00Neutral → Outperform
    Macquarie
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    Cal-Maine Foods Inc.
    $CALM
    12/1/2025$100.00Buy
    The Benchmark Company
    PureCycle Technologies Inc.
    $PCT
    11/24/2025$9.00Buy → Hold
    TD Cowen
    TAL Education Group
    $TAL
    10/30/2025$16.00Neutral → Overweight
    Analyst
    More analyst ratings

    $AMAM
    $ARBK
    $BXRX
    $CALM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for UKONIQ

    Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

    2/9/21 12:05:59 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $ARBK
    $BXRX
    $CALM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TAL Education upgraded by Macquarie with a new price target

    Macquarie upgraded TAL Education from Neutral to Outperform and set a new price target of $18.00

    1/30/26 6:41:31 AM ET
    $TAL
    Other Consumer Services
    Real Estate

    VistaGen downgraded by Jefferies with a new price target

    Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90

    12/17/25 2:23:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Maxim Group

    Maxim Group downgraded VistaGen from Buy to Hold

    12/17/25 12:23:57 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $ARBK
    $BXRX
    $CALM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Husby Jonathon B. bought $24,849 worth of shares (10,350 units at $2.40), increasing direct ownership by 12% to 94,608 units (SEC Form 4)

    4 - AEye, Inc. (0001818644) (Issuer)

    11/12/25 6:02:48 PM ET
    $LIDR
    Auto Parts:O.E.M.
    Consumer Discretionary

    Chief Strategy Officer Lombardo Keira L bought $258,599 worth of shares (2,800 units at $92.36), increasing direct ownership by 299% to 3,738 units (SEC Form 4)

    4 - CAL-MAINE FOODS INC (0000016160) (Issuer)

    10/6/25 7:46:52 PM ET
    $CALM
    Farming/Seeds/Milling
    Consumer Staples

    Large owner Hrt Financial Lp bought $43,736 worth of Class A Shares (546,706 units at $0.08) and sold $160,995 worth of Class A Shares (2,012,436 units at $0.08), increasing direct ownership by 1,035% to 1,347,044 units (SEC Form 4)

    4 - MULLEN AUTOMOTIVE INC. (0001499961) (Issuer)

    4/8/25 10:41:17 AM ET
    $MULN

    $AMAM
    $ARBK
    $BXRX
    $CALM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services

    MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has retained CORE IR, a leading investor relations, public relations, and strategic advisory firm, to assist the Company with public relations, shareholder communications, and social media management services. Nuwellis Chairman and CEO John Erb commented, "We believe CORE IR's integrated communications approach will enable us to more effectively articulate our value proposition to investors, partners, and key stakeholders. As we continue to expand our presence across the medical device and diag

    4/9/26 8:30:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

    LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investi

    4/9/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TAL Education Group to Announce Fourth Quarter and Fiscal Year 2026 Financial Results on April 23, 2026

    BEIJING, April 9, 2026 /PRNewswire/ -- TAL Education Group ("TAL" or the "Company") (NYSE:TAL), a smart learning solutions provider in China, today announced that it will release its unaudited financial results for the fourth quarter and fiscal year 2026 ended February 28, 2026,  before the market opens on Thursday, April 23, 2026. The Company will host a corresponding conference call and live webcast at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing Time) on Thursday, April 23, 2026.Please note that you will need to pre-register for conference call participation athttps://dpregister.com/sreg/10208034/103bc38d804.Upon registration, you will receive an email containing participant dial-in num

    4/9/26 5:00:00 AM ET
    $TAL
    Other Consumer Services
    Real Estate

    $AMAM
    $ARBK
    $BXRX
    $CALM
    SEC Filings

    View All

    SEC Form DEFA14A filed by TransCode Therapeutics Inc.

    DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

    4/7/26 8:37:01 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    4/7/26 8:35:16 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Nuwellis Inc.

    DEFA14A - Nuwellis, Inc. (0001506492) (Filer)

    4/6/26 4:30:41 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AMAM
    $ARBK
    $BXRX
    $CALM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tressler Nick B.

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    4/9/26 8:43:16 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Singh Shawn

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    4/9/26 8:41:53 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Prince Joshua S.

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    4/9/26 8:40:22 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $ARBK
    $BXRX
    $CALM
    Financials

    Live finance-specific insights

    View All

    TAL Education Group to Announce Fourth Quarter and Fiscal Year 2026 Financial Results on April 23, 2026

    BEIJING, April 9, 2026 /PRNewswire/ -- TAL Education Group ("TAL" or the "Company") (NYSE:TAL), a smart learning solutions provider in China, today announced that it will release its unaudited financial results for the fourth quarter and fiscal year 2026 ended February 28, 2026,  before the market opens on Thursday, April 23, 2026. The Company will host a corresponding conference call and live webcast at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing Time) on Thursday, April 23, 2026.Please note that you will need to pre-register for conference call participation athttps://dpregister.com/sreg/10208034/103bc38d804.Upon registration, you will receive an email containing participant dial-in num

    4/9/26 5:00:00 AM ET
    $TAL
    Other Consumer Services
    Real Estate

    Cal-Maine Foods Reports Third Quarter Fiscal 2026 Results

    RIDGELAND, Miss., April 01, 2026 (GLOBE NEWSWIRE) -- Cal-Maine Foods, Inc. (NASDAQ:CALM) ("Cal-Maine Foods," "we," "us," "our" or the "company"), the largest egg company in the United States and a leading player in the egg-based food industry, today reported results for its fiscal 2026 third quarter, ended February 28, 2026. Unless otherwise indicated, all comparisons are to the comparable period of fiscal 2025. Strategic Execution Highlights Continued focus on sales diversification and mix shift, expected to strengthen earnings durability and predictability over timeIn the third quarter of fiscal 2026: Specialty eggs sales increased to 50.5% of total shell egg sales, up 2,610 basis poin

    4/1/26 6:00:00 AM ET
    $CALM
    Farming/Seeds/Milling
    Consumer Staples

    Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

    Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended D

    3/30/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $ARBK
    $BXRX
    $CALM
    Leadership Updates

    Live Leadership Updates

    View All

    Cal-Maine Foods Welcomes Dudley D. Wooley to Board of Directors

    RIDGELAND, Miss., April 01, 2026 (GLOBE NEWSWIRE) -- Cal-Maine Foods, Inc. (NASDAQ:CALM), the largest egg company in the United States and a leading player in the egg-based food industry, today announced the appointment of Dudley D. Wooley to its Board of Directors. Mr. Wooley brings extensive leadership experience in risk management, business strategy, and governance, further strengthening the Board's depth of expertise as the Company continues executing its long-term growth strategy. Mr. Wooley currently serves as Chief Executive Officer of Ross & Yerger Insurance, Inc., a super-regional, employee-owned independent insurance agency headquartered in Jackson, Mississippi. With more than t

    4/1/26 6:00:00 AM ET
    $CALM
    Farming/Seeds/Milling
    Consumer Staples

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AMAM
    $ARBK
    $BXRX
    $CALM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gaotu Techedu Inc.

    SC 13G/A - Gaotu Techedu Inc. (0001768259) (Subject)

    11/27/24 6:02:40 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.

    SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

    11/14/24 7:45:34 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:13:38 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care